Objective To study the effect of ceftazidime combined with ambroxol on inflammatory factors and immune function of elderly diabetic patients with pulmonary infection .Methods A total of 112 elderly patients with diabetes com-plicated with pulmonary infection in Suining Central Hospital from Oct .2015 to Dec.2016 were divided into an observation group and a control group according to the treatment method ,56 patients each .The control group was given cefotaxime sodi-um combined with ambroxol therapy ,while the observatoin group was given ceftazidime combined with ambroxol therapy . After 2 weeks of treatment,the serum inflammatory factors,immune function,clinical efficacy,clinical symptoms improve-ment time and adverse reactions of the two groups were compared .Results The observation group′s effective rate was sig-nificantly higher than the control group′s[91.07%(51/56)vs 75.00%(42/56)](P<0.05).After treatment,fever,cough and expectoration improvement time of the observation group were significantly shorter than those of the control group [(35.42 ±4.21) h vs (41.36 ±5.26) h,(44.36 ±6.24) h vs (50.25 ±6.34) h](P<0.05).After treatment,serum tumor necrosis factor α,procalcitonin ,C reactive protein of the observation group were significantly lower than those of the control group[(31.14 ±3.45) ng/L vs (43.15 ±5.24) ng/L, (4.32 ±0.68) pg/L vs (7.12 ±1.14) pg/L,(56.24 ± 6.47) mg/L vs (75.36 ±9.52) mg/L](P<0.01).After treatment,CD3+, CD4+, CD4+/CD8+of the observation group were significantly higher than those of the control group [(62.35 ±6.24)%vs (59.78 ±6.15)%,(34.12 ±5.24)% vs (31.78 ±4.20)%,(1.20 ±0.34) vs (1.03 ±0.26)], CD8+ was significantly lower than that of the control group [(28.54 ±4.12)%vs (31.02 ±3.45)%](P<0.05).The complication rate in the observation group was significantly lower than that in the control group [7.14%(4/56) vs 21.43%(12/56)](P<0.05).Conclusion The combination of ceftazidime and ambroxol can improve the clinical efficacy and reduce the incidence of adverse reactions in elderly diabetic patients with pulmonary infection , which may be related to relieving inflammatory symptoms and improving immune func-tion.%目的 探讨头孢他啶联合氨溴索治疗对老年糖尿病合并肺部感染患者炎性因子及免疫功能的影响.方法 回顾性分析2015年10月至2016年12月遂宁市中心医院收治的112例老年糖尿病合并肺部感染患者的临床资料,依据治疗方法不同分为观察组和对照组,各56例.在控制血糖等常规治疗的同时,对照组给予头孢噻肟钠联合氨溴索治疗,观察组给予头孢他啶联合氨溴索治疗.治疗2周后,比较两组血清炎性因子、免疫功能、临床疗效、临床症状改善时间、不良反应等指标.结果 观察组有效率明显高于对照组[91.07%(51/56)比75.00%(42/56)](P<0.05).观察组发热、咳嗽咳痰改善时间明显短于对照组[(35.42±4.21)h比(41.36±5.26)h,(44.36±6.24)h比(50.25±6.34)h](P<0.05).治疗后,观察组血清肿瘤坏死因子α、降钙素原、C反应蛋白水平低于对照组[(31.14±3.45)ng/L比(43.15±5.24)ng/L,(4.32±0.68)pg/L比(7.12±1.14)pg/L,(56.24±6.47)mg/L比(75.36±9.52)mg/L](P<0.01).治疗后,观察组CD3+、CD4+、CD4+/CD8+明显高于对照组[(62.35±6.24)%比(59.78±6.15)%,(34.12±5.24)%比(31.78±4.20)%,(1.20±0.34)比(1.03±0.26)],CD8+明显低于对照组[(28.54±4.12)%比(31.02±3.45)%](P<0.05).观察组并发症发生率明显低于对照组[7.14%(4/56)比21.43%(12/56)](P<0.05).结论 头孢他啶联合氨溴索治疗有助于提高老年糖尿病合并肺部感染患者临床疗效,减少不良反应,这可能与缓解患者炎症症状、改善免疫功能等因素有关.
展开▼
